Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tafasitamab + bendamustine
- Development stage
- Preclinical
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Tafasitamab + bendamustine is a combination regimen consisting of **tafasitamab**, an Fc-modified, humanized monoclonal antibody targeting CD19, and **bendamustine**, an alkylating agent. Tafasitamab binds to CD19, a surface glycoprotein broadly expressed in B-cell malignancies, leading to tumor cell apoptosis, enhanced antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP) via Fcγ receptor interaction on effector cells such as NK cells and macrophages[2][5][6]. Bendamustine crosslinks DNA, resulting in cell death through apoptosis, and is commonly used in hematological malignancies. This combination is being investigated as a therapeutic regimen for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), especially in patients who are ineligible for autologous stem cell transplant (ASCT)[5]. As of September 2025, tafasitamab is approved in combination with lenalidomide, not bendamustine, for DLBCL, but the combination with bendamustine is being explored preclinically and in trials for B-cell lymphomas.
- Other names
- tafasitamab + bendamustine
02
Targets
Beyond the preview
Go deeper on tafasitamab + bendamustine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tafasitamab + bendamustine.